6 completed, 4 recruiting, 1 active not recruiting, 1 terminated. 12 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 6, Recruiting 4, Active not recruiting 1, Terminated 1 |
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
Follow Blood Cancer: new trials by email Literature Review of Blood Cancer trials Research Report on Blood Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial genotype-directed dosing with dosing software based on therapeutic drug monitoring - Fungal Infection, Haematological Malignancy | Phase 2 | Recruiting | The University of Queensland | 104 | 2025-04-14 | 2026-04-16 |
| Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue Time-restricted eating, Nutrition counseling - Neoplasms, Blood Cancer | Phase 2 | Recruiting | University of Maryland, Baltimore | 96 | 2024-11-04 | 2026-06-05 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation Isatuximab - Blood Cancer, Refractory Immune Cytopenias | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2023-07-21 | 2026-04-02 |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL MT-3724 Phase 1, MT-3724 Phase 2 - Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 / Phase 2 | Terminated | Molecular Templates, Inc. | 38 | 2015-02-01 | 2022-08-18 |
| Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors Cancer: Thriving and Surviving Online Workshop - Blood Cancer, Breast Cancer | Phase 2 | Completed | Stanford University | 585 | 2009-07-01 | 2013-02-07 |
| TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Total Lymphoid Irradiation (TLI), Anti-Thymocyte Globulin as Conditioning (ATG) - Myeloproliferative Disorders, Blood Cancer | Phase 2 | Completed | Stanford University | 77 | 2004-07-01 | 2015-03-18 |
| Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies Cyclosporine, Anti-thymocyte globulin (ATG), Mycophenolate mofetil (MMF) - Blood Cancer, Leukemia | Phase 2 | Completed | Stanford University | 303 | 2003-03-01 | 2021-06-29 |
| A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) Darbepoetin alfa - Blood Cancer, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Peter L Greenberg | 21 | 2002-02-01 | 2013-02-04 |
| Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide - Blood Cancer, Multiple Myeloma | Phase 2 | Completed | Wen-Kai Weng | 63 | 2000-08-01 | 2018-01-18 |
| Allogeneic Transplantation From Related Haploidentical Donors non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine - Blood Cancer, Leukemia | Phase 2 | Completed | Stanford University | 16 | 2000-08-01 | 2019-12-04 |
Hematologic Neoplasms (12) · Neoplasms (5) · Leukemia (4) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Communicable Diseases (1) · Fatigue (1) · Feeding Behavior (1) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Infections (1) · Intermittent Fasting (1)
Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Neoplasms by Site (12) · Neoplasms (7) · Neoplasms by Histologic Type (6) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Pathological Conditions, Signs and Symptoms (4) · Lymphatic Diseases (3) · Pathologic Processes (3) · Blood Protein Disorders (2) · Bone Marrow Diseases (2) · Cardiovascular Diseases (2) · Disease Attributes (2)
Antilymphocyte Serum (3) · Cyclosporine (3) · Granulocyte Colony-Stimulating Factor (3) · Mycophenolic Acid (3) · Cyclophosphamide (2) · Filgrastim (2) · isatuximab (2) · Acetaminophen (1) · Azacitidine (1) · Darbepoetin alfa (1) · Diphenhydramine (1) · Hydrocortisone (1) · Interleukin-2 (1) · Melphalan (1) · Mesna (1)
Stanford University (4) · Indapta Therapeutics, INC. (1) · Jacqueline Garcia, MD (1) · Memorial Sloan Kettering Cancer Center (1) · Molecular Templates, Inc. (1) · Peter L Greenberg (1) · The University of Queensland (1) · University of Maryland, Baltimore (1) · Wen-Kai Weng (1)
United States (12) · Australia (1) · Belarus (1) · Canada (1) · Georgia (1) · Israel (1) · Moldova (1) · Poland (1) · Serbia (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Robert Lowsky (3) · Jacqueline Garcia, MD (1) · Jason A Roberts, PhD (1) · Kate R Lorig (1) · Michael Scorder, MD (1) · Peter L Greenberg (1) · Wen-Kai Weng, MD (1)
PMID 16192477, PMID 19423725, PMID 20528878, PMID 24566820, PMID 24607552, PMID 26146806, PMID 41174725